Devita, Hellman, and Rosenberg's Cancer

LWBK1006-11 LWW-Govindan-Review November 24, 2011 11:21

Chapter 11•Systemic Therapy for Cancer 125

Question 11.10. Which of the following best describes the mechanism of action for vinca

alkaloids?

A. Binds to tubulin and alters the tubulin dissociation rate

B. Binds and stabilizes tubulin resulting in cell cycle arrest

C. Binds to tubulin and alters the tubulin association rate

D. Promotion of tubulin polymerization resulting in cell cycle arrest

Question 11.11. Which of the following is NOT CORRECT with regard to therapy with

azacitidine?

A. Azacitidine can be given via intravenous infusion or subcutaneous

injection

B. The mechanism of action of azacitidine is via inhibition of DNA

methylation

C. Azacitidine has a short stability period after reconstitution in an aque-

ous solution

D. Efficacy with azacitidine should be assessed after two cycles of

therapy

Question 11.12. Which of the following is CORRECT regarding hemorrhagic cystitis?

A. Bladder protection with mesna is required for all patients receiving

cyclophosphamide

B. Hemorrhagic cystitis is caused by direct damage to the bladder wall

by cyclophosphamide or ifosfamide

C. Mesna works by providing a free sulfhydryl group that binds to the

metabolite and neutralizes it

D. Mesna should be given in divided doses to total 100% of the total

dose of cyclophosphamide or ifosfamide

Question 11.13. Which of the following is CORRECT regarding platinum analogs?

A. Carboplatin is associated with pronounced ototoxicity and should be

avoided in patients with baseline hearing difficulty

B. Infusions with magnesium and calcium prior to and after oxaliplatin

therapy may lessen the severity and incidence of peripheral neuropa-

thy

C. Cisplatin is associated with an acute neuropathy exacerbated by cold

food or beverages

D. Oxaliplatin is associated with significant renal toxicity and should be

avoided in patients with renal insufficiency